High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N.
Hattori Y, et al. Among authors: ishiguro n.
Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2.
Mod Rheumatol. 2018.
PMID: 28463029